microdosing glp 1 drugs Why we launched Noom's Microdose GLP-1Rx Program Microdosing Ozempic for Weight Loss:

Description

Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate

(Updated 2022 Nov 14)

Treatment with survodutide has not shown unexpected safety or tolerability issues

Combining insights from the ESG Risk Rating and Morningstar Equity Research, we find that Roche and Pfizer stand out as potential top choices among the companies poised to enter the GLP-1 space